2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Neoplasms
10
Leukemia, Myeloid, Acute
6
Myelodysplastic Syndromes
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia
2
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Lymphoma, T-Cell
1
Lymphoma
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Erythroblastic, Acute
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cytarabine
75
Etoposide
31
Daunorubicin
27
Filgrastim
24
Mitoxantrone
23
Idarubicin
23
Busulfan
22
Peripheral Blood Stem Cell Transplantation
20
Cyclophosphamide
20
fludarabine phosphate
19
Gemtuzumab
14
tipifarnib
11
Antilymphocyte Serum
11
Radiotherapy
10
Methotrexate
10
Cyclosporine
10
Clofarabine
10
sargramostim
9
Gene Expression Profiling
9
Flow Cytometry
9
Azacitidine
9
alvocidib
6
aldesleukin
6
Whole-Body Irradiation
6
Vorinostat
6
Topotecan
6
Tacrolimus
6
Bortezomib
6
valspodar
5
Melphalan
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Erythroblastic, Acute
×
BI 6727
×
Clear all
NCT02527174
2017-04-05
VIAC
University of Alberta
Phase 1
Withdrawn